Aktis Operating Cycle from 2010 to 2026
| AKTS Stock | USD 20.25 0.61 3.11% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Aktis Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aktis Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Selling General Administrative of 9.1 M or Other Operating Expenses of 31.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0. Aktis financial statements analysis is a perfect complement when working with Aktis Oncology Valuation or Volatility modules.
Aktis | Operating Cycle | Build AI portfolio with Aktis Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aktis Stock Analysis
When running Aktis Oncology's price analysis, check to measure Aktis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aktis Oncology is operating at the current time. Most of Aktis Oncology's value examination focuses on studying past and present price action to predict the probability of Aktis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aktis Oncology's price. Additionally, you may evaluate how the addition of Aktis Oncology to your portfolios can decrease your overall portfolio volatility.